{"id":"lum","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL5174683","moleculeType":null,"molecularWeight":"429.39"},"_dailymed":{"setId":"4b0c2213-8667-be6f-e063-6394a90a5e86","title":"LUMINESCE DAILY MOISTURIZING COMPLEX (AVOBENZONE, OCTINOXATE, OCTISALATE, OCTOCRYLENE) CREAM [VELOVITA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LUM001 works by inhibiting tankyrase, which stabilizes β-catenin and activates Wnt signaling in intestinal epithelial cells. This mechanism promotes intestinal stem cell proliferation and differentiation, enhancing intestinal barrier integrity and regeneration. It is designed to treat conditions characterized by intestinal epithelial damage or dysfunction.","oneSentence":"LUM001 is a β-catenin modulator that enhances Wnt/β-catenin signaling to promote the expansion and function of intestinal stem cells and barrier function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:37.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Short bowel syndrome (SBS)"}]},"trialDetails":[{"nctId":"NCT07235033","phase":"PHASE2","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-23","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":60},{"nctId":"NCT07403643","phase":"PHASE4","title":"Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":"Uncomplicated Malaria","enrollment":60},{"nctId":"NCT02584244","phase":"PHASE1, PHASE2","title":"Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","status":"RECRUITING","sponsor":"Lumicell, Inc.","startDate":"2016-08-04","conditions":"Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer","enrollment":66},{"nctId":"NCT03834272","phase":"PHASE1, PHASE2","title":"Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies","status":"COMPLETED","sponsor":"Lumicell, Inc.","startDate":"2019-03-18","conditions":"Peritoneal Metastases","enrollment":18},{"nctId":"NCT07164209","phase":"NA","title":"The Remeasure Trial","status":"COMPLETED","sponsor":"Azienda Ospedaliera Ordine Mauriziano di Torino","startDate":"2022-01-02","conditions":"Ileocolic Crohn Disease, Kono S Anastomosis, Resection of the Mesentery","enrollment":73},{"nctId":"NCT05520359","phase":"NA","title":"Spinal Stimulation and Mobility Devices","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-08-04","conditions":"Cerebral Palsy, Stroke, Premature Birth","enrollment":20},{"nctId":"NCT06805084","phase":"","title":"Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2024-12-01","conditions":"Breast Adenocarcinoma, Luminal B Breast Cancer","enrollment":80},{"nctId":"NCT04440982","phase":"PHASE2","title":"Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients","status":"TERMINATED","sponsor":"Lumicell, Inc.","startDate":"2020-09-01","conditions":"Breast Cancer, Neoadjuvant Therapy","enrollment":98},{"nctId":"NCT03717142","phase":"NA","title":"Feasibility of the LUM Imaging System for Detection of Cancer to the Brain","status":"TERMINATED","sponsor":"Lumicell, Inc.","startDate":"2019-05-03","conditions":"Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain","enrollment":4},{"nctId":"NCT04546633","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-16","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":295},{"nctId":"NCT04235140","phase":"PHASE3","title":"Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-24","conditions":"Cystic Fibrosis","enrollment":52},{"nctId":"NCT04276909","phase":"NA","title":"Feasibility Study of LUM Imaging System for Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Lumicell, Inc.","startDate":"2026-01","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT03686215","phase":"PHASE3","title":"Investigation of Novel Surgical Imaging for Tumor Excision","status":"COMPLETED","sponsor":"Lumicell, Inc.","startDate":"2019-11-04","conditions":"Breast Cancer","enrollment":406},{"nctId":"NCT03321929","phase":"PHASE2","title":"Intraoperative Detection of Residual Cancer in Breast Cancer","status":"COMPLETED","sponsor":"Lumicell, Inc.","startDate":"2018-02-06","conditions":"Breast Cancer","enrollment":234},{"nctId":"NCT03601637","phase":"PHASE3","title":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-09-07","conditions":"Cystic Fibrosis","enrollment":61},{"nctId":"NCT02438358","phase":"PHASE1, PHASE2","title":"Feasibility Study of Intraoperative Imaging in Breast Cancer","status":"COMPLETED","sponsor":"Lumicell, Inc.","startDate":"2015-06","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT03625466","phase":"PHASE2","title":"A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-10","conditions":"Cystic Fibrosis","enrollment":51},{"nctId":"NCT03441464","phase":"PHASE1, PHASE2","title":"Feasibility of the LUM Imaging System for Detection of Prostate Cancer","status":"TERMINATED","sponsor":"Lumicell, Inc.","startDate":"2019-03-20","conditions":"Prostate Cancer, Neoplasm, Residual","enrollment":9},{"nctId":"NCT03167242","phase":"PHASE2","title":"Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-02","conditions":"Acute Uncomplicated Plasmodium Falciparum Malaria","enrollment":524},{"nctId":"NCT02544451","phase":"PHASE3","title":"Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":246},{"nctId":"NCT04623879","phase":"","title":"Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2016-12-29","conditions":"Cystic Fibrosis","enrollment":13},{"nctId":"NCT03125395","phase":"PHASE3","title":"A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-05-12","conditions":"Cystic Fibrosis","enrollment":57},{"nctId":"NCT03565692","phase":"","title":"Lum-Iva-biota: Exploring the Respiratory Mycobiota and Microbiota Profile in French CF Patients Taking Lumacaftor-Ivacaftor","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2018-07-01","conditions":"Cystic Fibrosis","enrollment":250},{"nctId":"NCT02875366","phase":"PHASE4","title":"A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-09","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT02797132","phase":"PHASE3","title":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-05","conditions":"Cystic Fibrosis","enrollment":62},{"nctId":"NCT03061331","phase":"PHASE2","title":"Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-31","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT02823470","phase":"PHASE4","title":"A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-06","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT02514473","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-07","conditions":"Cystic Fibrosis","enrollment":206},{"nctId":"NCT01897233","phase":"PHASE3","title":"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-07","conditions":"Cystic Fibrosis","enrollment":62},{"nctId":"NCT01931839","phase":"PHASE3","title":"A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-10","conditions":"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation","enrollment":1164},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT01807949","phase":"PHASE3","title":"A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-04","conditions":"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","enrollment":563},{"nctId":"NCT01225211","phase":"PHASE2","title":"Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-10","conditions":"Cystic Fibrosis","enrollment":312},{"nctId":"NCT01807923","phase":"PHASE3","title":"A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-05","conditions":"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","enrollment":559}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1658,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lumacaftor","VX-809"],"phase":"marketed","status":"active","brandName":"LUM","genericName":"LUM","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LUM001 is a β-catenin modulator that enhances Wnt/β-catenin signaling to promote the expansion and function of intestinal stem cells and barrier function. Used for Short bowel syndrome (SBS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}